Issue 40 - Oct 25, 2019
  • NCI to extend Cancer Center Support Grant period to seven years for qualifying cancer centers

    NCI-designated cancer centers will soon be able to extend their Cancer Center Support Grant award period from five years to seven years, depending on merit at peer review, sustained exceptional progress, stability, and longevity of the cancer center.

  • Conversation with The Cancer Letter

    Ciolino: CCSG extension will give cancer centers more freedom, time, resources to increase scientific impact

    By allowing cancer centers to extend their Cancer Center Support Grant award period from five to seven years, NCI hopes to enable eligible centers to spend less time preparing for a grant renewal in favor of conducting more research and setting long-term goals.

  • Obituary

    Bernard Fisher, pioneering breast cancer researcher, dies at 101

    Bernard Fisher, a surgeon and clinical trialist who revolutionized the field of breast cancer research and all but eliminated reliance on disfiguring surgeries, died Oct. 16 at the age of 101.

  • Aberle, DuBois, Gupta, Jaffee, Mardis among new members of the National Academy of Medicine

    The National Academy of Medicine announced the election of 90 regular members and 10 international members during its annual meeting Oct. 21.

  • In Brief

    • Sleckman to lead O’Neal Comprehensive Cancer Center
    • Michael Birrer named director of  UAMS Winthrop P. Rockefeller Cancer Institute
    • Lowy, Huntsman family among recipients of AACI/CCAF awards
    • Yale Cancer Center announces leadership appointments
    • Jyoti Patel joins Lurie Cancer Center leadership
    • UA Cancer Center Receives $8.6M grant to lead NCI Clinical Trials Network
    • House drug price plan would lower costs for some cancer drugs, but is unlikely to pass in Senate
    • IAEA and St. Jude to tackle childhood cancers in developing countries
    • Aflac Cancer and Blood Disorders program receives $20 million for pediatric cancer trials
  • TCCL Logo

  • Clinical Roundup

    • Phase III IMbrave150 study demonstrates improved OS + PFS in liver cancer
    • Novel imaging technology could reduce need for additional surgery after breast cancer resection
    • Why targeted immuno-oncology drugs sometimes fail
    • Antibody eradicates leukemia stem cells
    • CheckMate-9LA meets OS primary endpoint
  • Drugs & Targets

    • FDA approves indication for Zejula in advanced ovarian, fallopian tube, or primary peritoneal cancer
    • FDA approves test to identify patients eligible for treatment with Zejula in late-line Ovarian Cancer
    • European Commission approves dosing schedules for Opdivo in melanoma
    • FDA approves Fast Track designation for bemcentinib in AML indication
    • Abernethy, Shuren, issue statement on FDA breast implant labelling guidance
    • FDA grants first-ever modified risk orders to eight smokeless tobacco products
Issue 39 - Oct 18, 2019
  • E-cigarette smoke associated with lung cancer, inflammation, as federal agencies respond to vaping deaths

    E-cigarette smoke, like tobacco smoke, may, in fact, cause cancer, new studies suggest.

    According to one just-reported study, mice exposed to e-cigarette smoke were five times more likely to develop lung cancer, and 10 times more likely to develop precancerous lesions of the bladder.

  • Guest Editorial

    Museum malignancy:

    What the Sacklers and Philip Morris have in common

    Since March 2018, P.A.I.N. (Prescription Addiction Intervention Now), an organization founded in 2017 by photographer Nan Goldin, has held demonstrations at art museums in New York, Washington, DC, Boston, London and Paris to protest their acceptance of money from the Sackler family, owners of Purdue Pharma, a company that been accused of fomenting the prescription opioid addiction crisis.

  • In Brief

    • Brown named Syapse chief medical officer
    • Barker, Fingert, Hayes-Jordan and Vadaparampil named to NCAB
    • Virginia Tech announces cancer research initiative
    • Ribas, Jaffee, Eshhar, Samelson, Seed and Weiss share Coley awards for immunology
    • Cambridge’s Nik-Zainal wins Josef Steiner Cancer Research prize
    • Backman named associate director for research technology at Northwestern
    • City of Hope provides cancer support services to Amazon employees 
    • NCI grant UNC to help patients navigate costs of cancer care
    • Third Edition of Cancer Atlas highlights patterns and inequities in cancer burden
  • TCCL Logo

  • Real World Evidence

    Real-world data, evidence should be leveraged in clinical research to better include and ultimately treat larger patient populations

    The growth of personalized medicine in oncology continues to fuel a shift from traditional chemotherapies to immunotherapy. Currently, there are more than 30 immunotherapies approved for use in the United States, with more than 2,300 immunotherapy clinical trials listed on

  • Clinical Roundup

    • UCLA opens CAR T-cell trial focused on the most common types of lymphoma, leukemia
    • Results from STELLAR trial in MPM published in The Lancet Oncology
    • IASLC invites comments on “Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens Following Neoadjuvant Therapy”
    • Expert second opinion improves reliability of melanoma diagnoses
  • Drugs & Targets

    • Xenikos receives Fast Track designation for T-Guard for steroid-refractory SR-aGVHD
    • Flatiron announces clinical decision support application through Epic’s App Orchard
Issue 38 - Oct 11, 2019